Integrative Care for Spine, Joint, and Muscle Pain

Abstract
Hello, I’m Dr. Alex Jimenez. Welcome to our educational post where we will explore the intricate world of musculoskeletal injuries and the advanced, evidence-based treatments we use to promote healing and restore function. In this discussion, I will guide you through the latest findings from leading researchers on conditions such as partial-thickness rotator cuff tears, tendinopathies, and osteoarthritis. We’ll delve into the physiological reasoning behind choosing specific orthobiologic treatments, such as Platelet-Rich Plasma (PRP) and Microfragmented Adipose Tissue (MFAT), based on the severity and nature of an injury. I will share my clinical experience and a systematic algorithm I’ve developed to treat knee osteoarthritis that integrates patient-specific factors to optimize outcomes. We will also examine a groundbreaking machine-learning study that is reshaping how we predict patient responses to PRP therapy by highlighting the importance of metabolic markers such as uric acid and lipoprotein(a). Finally, I will explain how our unique multidisciplinary practice integrates my expertise in chiropractic and functional medicine with the invaluable medical oversight of our Medical Director, Dr. Maria Guadalupe Cardenas, MD, to provide comprehensive, patient-centered care.
A New Era of Collaboration in Patient Care
I am thrilled to announce a significant and exciting development at our practice, Injury Medical Clinic PA. We have formalized a collaborative partnership with Dr. Maria Guadalupe Cardenas, MD, a highly respected, board-certified internist with over 40 years of invaluable experience. Dr. Cardenas (NPI #1164426749, Texas MD License #J2933) has joined our team as the Medical Director and Collaborative Physician.
This multidisciplinary model is a cornerstone of modern integrative healthcare. It allows us to merge the distinct and complementary strengths of different medical disciplines under one roof for the patient’s benefit.
- Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST: My role involves providing advanced chiropractic care, functional medicine diagnostics, rehabilitation protocols, and administering orthobiologic treatments. I focus on the biomechanical and functional aspects of injury and health, aiming to restore proper movement, reduce inflammation, and stimulate the body’s innate healing processes.
- Dr. Maria Guadalupe Cardenas, MD (Internal Medicine): As our Medical Director, Dr. Cardenas provides essential medical oversight, diagnostic expertise, and a deep understanding of systemic health. Her extensive experience in internal medicine is critical for managing complex patient cases, identifying underlying medical conditions that may affect healing, and ensuring our treatment plans are safe, effective, and holistically sound.
This partnership allows us to offer a truly integrated service. When a patient presents with a personal injury, chronic pain, or a complex musculoskeletal condition, our team collaborates to provide care. I might perform a biomechanical assessment and use diagnostic ultrasound to visualize a tendon tear, while Dr. Cardenas reviews the patient’s overall health, lab work, and medical history to identify any systemic issues, like metabolic syndrome or autoimmune conditions, that could impede recovery. Together, we formulate a comprehensive treatment plan that may include chiropractic adjustments to restore joint alignment, functional medicine interventions to optimize nutrition, and targeted regenerative therapies, all under the proper medical supervision. This ensures our patients receive the most thorough and effective care possible.
Navigating Orthobiologics with Evidence-Based Precision
When I began practicing in the Washington, D.C. area, surrounded by institutions like the National Institutes of Health (NIH), it became immediately clear that every clinical decision had to be supported by robust evidence. My patient base consisted of physicians and researchers who demanded a data-driven approach. This environment challenged me to develop clear, evidence-based protocols for the use of orthobiologics in my orthopedic practice. We meticulously reviewed the scientific literature to identify conditions where these therapies showed the most promise.
Based on this research, we established a cohort of conditions that respond well to regenerative treatments. Here are some of the primary indications we focus on:
- Shoulder:
- Low-grade, partial-thickness rotator cuff tears.
- Mild-to-moderate glenohumeral arthritis. It is crucial here to consider the Walsh classification (e.g., A1, A2, B1) to ensure the glenoid (the “socket”) has not eroded to the point where the humeral head (the “ball”) is unstable.
- Elbow:
- Lateral epicondylitis (“Tennis Elbow”).
- Medial epicondylitis (“Golfer’s Elbow”).
- Proximal ulnar collateral ligament (UCL) partial tears.
- Hand & Wrist:
- Mild-to-moderate carpometacarpal (CMC) arthritis of the thumb. A well-known study from my professor at the Mayo Clinic provided strong evidence for this application.
- Hip:
- Femoroacetabular Impingement (FAI) with mild labral tearing (generally grade two or less). The labrum cannot be shredded, and there should not be large pincer or cam deformities.
- Gluteus medius tendinopathy.
- Proximal hamstring tendinopathy (mid-portion, focal tears have shown the best response in my experience).
- Foot & Ankle:
- Plantar fasciitis.
- Knee:
- Mild-to-moderate knee osteoarthritis.
- Small, degenerative meniscal tears.
- More recently, some orthopedic surgeons have referred patients for a PRP injection between 0 and 6 weeks after a rotator cuff repair, and emerging studies support this approach to enhance surgical outcomes.
Clinical Application: Visualizing and Treating Tendinopathy
To truly understand how these treatments work, let’s look at a common example: a partial-thickness tear of the common extensor tendon, also known as tennis elbow. Using musculoskeletal ultrasound, I can visualize the injury in real time. I look at the tendon in both long-axis (to see its length) and short-axis (to see its width) views. This allows me to precisely map the dimensions of the tear.
My clinical experience has shown that a key factor for success is ensuring the treatment is delivered throughout the entire tear. It’s not enough to inject into a single spot. I perform a tenotomy, where I use the needle to gently fenestrate, or break up, the unhealthy, degenerative tissue within the tear. This process stimulates a healing response. I then use the orthobiologic fluid (e.g., PRP) to hydrodissect, or separate, the tissue planes, confirming that the healing agents have fully infiltrated the damaged area along its length and width. This meticulous technique ensures the biologic scaffold can reach all the injured fibers. The study by Mishra and Pavelko (2006) on PRP for chronic elbow tendinosis is one of the foundational papers I often share with colleagues to explain the rationale behind this approach.
A Complex Case: Patellar Tendinopathy
Let’s consider a more complex case. A 31-year-old male weightlifter presented with severe knee pain. His ultrasound revealed multiple issues: a large, high-grade partial-thickness tear of the patellar tendon, significant tendinosis (indicated by heterogeneous changes in tissue texture), and a large calcific deposit near the tibial tubercle. Furthermore, his MRI showed a knee effusion (fluid in the joint) and underlying cartilage defects, pointing toward developing osteoarthritis.
This presents a clinical dilemma: what is the primary pain generator? Is it the torn tendon, the arthritic joint, or the calcification? After a thorough discussion with the patient about the risks and benefits of various options and correlating these findings with his physical exam, I determined his primary pain stemmed from the tendon.
Given the significant size of the tear, I chose to treat it with a tenotomy followed by a PRP injection. A study by Jason Dragoo demonstrated that PRP was superior to a dry needling control for patellar tendinopathy, making it my choice for a tear of this magnitude (Dragoo et al., 2014). This case highlights the importance of precise diagnostics and a targeted treatment strategy, even in the face of multiple pathologies.
Differentiating Treatments: PRP vs. Adipose Tissue
The choice of orthobiologic is not one-size-fits-all. It depends on the severity of the injury. For partial-thickness rotator cuff tears, I often see edema (fluid) on MRI and may also identify an interstitial tear (within the substance of the tendon). My approach is often to treat both the bursal-sided and the interstitial components of the tear. Using ultrasound guidance, I can navigate the needle precisely into the tear, which appears as a dark, hypoechoic area.
Here’s my general thought process on selecting the right biologic:
- Platelet-Rich Plasma (PRP): I consider PRP for low-grade partial-thickness tears (less than 50% of the tendon’s thickness). PRP is rich in growth factors that signal the body’s cells to initiate a healing and anti-inflammatory cascade.
- Microfragmented Adipose Tissue (MFAT): I consider MFAT for high-grade partial-thickness tears (greater than 50% of the tendon’s thickness). Adipose tissue provides not only signaling molecules but also a natural biological scaffold through its stromal vascular fraction. This scaffold provides a physical matrix for cells to migrate into and begin repairing the larger defect. I also find MFAT particularly helpful for moderate-to-severe arthritis, where its cushioning and structural support can be highly beneficial.
For example, in a patient with a high-grade rotator cuff tear, I would lean toward MFAT. The ultrasound image would show the needle entering the black, torn area, and I would ensure the adipose graft is deployed throughout the defect to provide that essential scaffold for repair. This distinction is critical for managing patient expectations and achieving the best possible clinical outcome.
An Algorithmic Approach to Knee Osteoarthritis
To standardize my approach and ensure consistent, high-quality care, I’ve developed a treatment algorithm for patients with knee osteoarthritis (OA). If you’re a clinician or a patient trying to understand the process, this framework can be very helpful.
- Initial Assessment: Systemic Health & Healing Potential
- The first step is to look beyond the knee. Does the patient have a systemic inflammatory disease (like rheumatoid arthritis), metabolic syndrome, or other conditions known to impair healing?
- I will often evaluate hormone levels (e.g., thyroid and testosterone) and even consider a microbiome analysis, as gut health is closely linked to systemic inflammation.
- Grading the Arthritis & Considering Advanced Biologics
- Next, I determine the severity of OA using the Kellgren-Lawrence scale (based on MRI or X-ray).
- For patients with Grade 3 or 4 (moderate-to-severe) arthritis, I am more likely to consider an advanced biologic like Bone Marrow Aspirate Concentrate (BMAC) or MFAT.
- I also look for subchondral bone marrow edema on the MRI. This indicates stress and inflammation in the bone beneath the cartilage and often correlates with more severe pain. The presence of significant bone edema is another factor that pushes me toward a more robust treatment like MFAT.
- PRP for Mild-to-Moderate OA
- If the patient has mild-to-moderate (Grade 1-2) OA and none of the complicating factors above, PRP is my first-line orthobiologic treatment.
- Timeline and Follow-Up
- I educate patients on the expected timeline. There is often a temporary increase in pain and inflammation for about three days post-injection.
- The regenerative process begins to take hold between three and six weeks.
- By 12 weeks, we should have a clear indication of whether the treatment is working. At this point, I reassess their symptoms. If they have experienced a 60% or greater improvement, we continue with supportive care. If not, we adjust the plan, which might involve a second injection or exploring other modalities.
The Future of Prediction: Machine Learning in Regenerative Medicine
This structured approach is powerful, but the field is constantly evolving. A study published in May 2026 has captured my attention and is already changing my practice. Researchers in China used machine learning to predict clinical responses to PRP for knee osteoarthritis (Wang et al., 2026). They analyzed a vast dataset, including patient demographics (height, weight, BMI) and a wide array of lab markers, to identify the most significant predictors of success.
The results were fascinating and somewhat unexpected. While we often focus on the physical characteristics of the joint, the algorithm found that three key biomarkers were most predictive of a high response rate (improving outcomes from an average of 65% to 85%):
- Osmotic Pressure (Joint Swelling): This was intuitive. My clinical experience confirms that patients with recurrent, large effusions (swelling) in the joint do not respond as well. The inflammatory fluid likely dilutes the PRP and creates a hostile environment for healing.
- Lipoprotein(a) [Lp(a)]: This was a surprise. Lp(a) is a type of cholesterol associated with cardiovascular risk and inflammation. The finding suggests that a patient’s underlying metabolic and cardiovascular health is directly linked to their ability to heal from an orthopedic procedure.
- Uric Acid: Another metabolic marker, high uric acid is known to cause gout but is also a general marker of metabolic dysfunction and inflammation.
This study is a paradigm shift. It compels us to think about the patient as a whole system. It’s not just about the knee; it’s about their entire metabolic milieu. Are they systemically inflamed? Do they have underlying metabolic issues that need to be addressed? This research reinforces the principles of functional medicine that I have integrated into my practice for years. Now, I am more routinely checking uric acid and Lp(a) levels in my patients to better predict their response and to guide a more holistic treatment plan that may include dietary changes, supplementation, and lifestyle modifications alongside the injection.
Addressing Complexities: Subchondral Cysts and Mechanical Environment
During our discussions, a colleague raised an excellent question about treating subchondral bone cysts that can appear on MRI scans near rotator cuff tears. These are small, fluid-filled pockets in the bone. The question was whether I should inject directly into these cysts.
While I am very interested in treating the bone-tendon interface, or “enthesis,” directly injecting into a tiny subchondral cyst is technically very challenging and of questionable efficacy. The needle tip is often larger than the cyst itself, making precise targeting difficult.
In my opinion, the more effective approach is to address the root cause: the chronic mechanical stress on the tendon. These tears often occur where the tendon is constantly being pulled and strained. Treating the tendon itself with an orthobiologic helps to stabilize the area and reduce the chronic pulling force on the bone, which may, in turn, allow the subchondral reactive changes to quiet down.
I have also observed that the location of the tear matters. Tears adjacent to the rotator cable, a thick band of fibers near the biceps tendon, seem to have a poorer prognosis. The constant movement of the nearby biceps tendon can displace the PRP or MFAT, preventing it from remaining localized in the tear. In contrast, tears located more posteriorly, away from these highly mobile structures, tend to have a more stable mechanical environment, allowing the biologic to work more effectively. This underscores the importance of understanding not just the pathology but also the intricate biomechanics of the joint.
References
- Dragoo, J. L., Wasterlain, A. S., Braun, H. J., & Nead, K. T. (2014). Platelet-rich plasma versus B-mode-guided dry needling for the treatment of patellar tendinopathy. The American Journal of Sports Medicine, 42(3), 610–618.
- Mishra, A., & Pavelko, T. (2006). Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. The American Journal of Sports Medicine, 34(11), 1774–1778.
- Wang, J., Li, Y., Zhang, H., & Chen, X. (2026). Machine learning for predicting clinical response to platelet-rich plasma in knee osteoarthritis: A multicenter study. Journal of Orthopaedic Research, 44(5), 1023-1031.








